ETF Holdings Breakdown of HALO

HALO institutional holdings

Date	ETF ISIN/Name	Num Shares	Book value
2025-10-17	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	49,721	USD 3,332,799
2025-10-17	IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc))	151,640	USD 10,164,429
2025-10-17	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	74,077	USD 4,965,381
2025-10-17	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	74,077	USD 4,965,381
2025-10-17	IE000NITTFF2 (iShares Russell 1000 Growth UCITS ETF)	1,860	USD 124,676
2025-10-17	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	88,945	USD 5,961,983 1.0%
2025-10-17	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	2,016	USD 135,132 1.0%
Total =		442,336	USD 29,649,781

Book value of shares is calculated on the adjusted close price of each day (row).

News associated with HALO

Notable ETF Outflow Detected - XBI, ALNY, HALO, INSM

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $119.6 million dollar outflow -- that's a 2.2% decrease week over week - 2025-08-28 11:56:11

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Receives Consensus Recommendation of “Hold” from Analysts

Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) has been assigned a consensus rating of “Hold” from the eleven research firms that are covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, five have assigned a hold recommendation and four have issued a buy recommendation on the […] - 2025-08-26 02:16:51

Halozyme Therapeutics (NASDAQ:HALO) Sets New 52-Week High Following Analyst Upgrade

Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report)’s stock price hit a new 52-week high during mid-day trading on Tuesday after Morgan Stanley raised their price target on the stock from $75.00 to $80.00. Morgan Stanley currently has an overweight rating on the stock. Halozyme Therapeutics traded as high as $70.70 and last traded at […] - 2025-08-20 02:34:49

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Position Lessened by Vanguard Group Inc.

Vanguard Group Inc. trimmed its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 3.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,831,503 shares of the biopharmaceutical company’s stock after selling 450,211 shares during […] - 2025-08-13 05:43:01

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. decreased its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 1.9% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,748,851 shares of the biopharmaceutical company’s stock after selling 34,326 shares during […] - 2025-08-12 05:24:49

Halozyme Therapeutics (NASDAQ:HALO) Upgraded to “Overweight” at Morgan Stanley

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) was upgraded by analysts at Morgan Stanley from an “equal weight” rating to an “overweight” rating in a report released on Wednesday, Marketbeat Ratings reports. The brokerage currently has a $75.00 price objective on the biopharmaceutical company’s stock, up from their previous price objective of $62.00. Morgan Stanley’s […] - 2025-08-08 02:40:46

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Stock Holdings Boosted by LPL Financial LLC

LPL Financial LLC lifted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 17.1% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 242,432 shares of the biopharmaceutical company’s stock after acquiring an additional 35,429 shares during the period. LPL Financial LLC’s holdings in […] - 2025-08-07 04:46:47

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Receives $62.70 Consensus Price Target from Analysts

Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) have earned an average recommendation of “Hold” from the twelve analysts that are presently covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell rating, six have issued a hold rating and four have issued a buy rating on the company. […] - 2025-08-04 02:59:02

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Acquired by IFP Advisors Inc

IFP Advisors Inc increased its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 2,374.1% during the first quarter, HoldingsChannel.com reports. The fund owned 2,103 shares of the biopharmaceutical company’s stock after buying an additional 2,018 shares during the period. IFP Advisors Inc’s holdings in Halozyme Therapeutics were worth $134,000 as of its most […] - 2025-07-29 04:32:50

Envestnet Asset Management Inc. Acquires 1,161 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Envestnet Asset Management Inc. raised its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 0.4% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 303,774 shares of the biopharmaceutical company’s stock after acquiring an additional 1,161 shares during […] - 2025-07-17 04:50:57

Teacher Retirement System of Texas Sells 3,278 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Teacher Retirement System of Texas trimmed its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 8.7% in the first quarter, Holdings Channel reports. The institutional investor owned 34,238 shares of the biopharmaceutical company’s stock after selling 3,278 shares during the quarter. Teacher Retirement System of Texas’ holdings in Halozyme Therapeutics were worth $2,185,000 […] - 2025-07-10 05:14:10

Analysts Set Halozyme Therapeutics, Inc. (NASDAQ:HALO) PT at $61.90

Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) has received a consensus rating of “Hold” from the twelve research firms that are covering the firm, MarketBeat reports. Two analysts have rated the stock with a sell rating, six have issued a hold rating and four have issued a buy rating on the company. The average […] - 2025-07-10 03:07:07

Principal Financial Group Inc. Has $24.25 Million Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Principal Financial Group Inc. grew its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 1.0% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 380,021 shares of the biopharmaceutical company’s stock after buying an additional 3,826 shares during the quarter. Principal Financial Group […] - 2025-07-09 05:51:39

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Vontobel Holding Ltd.

Vontobel Holding Ltd. decreased its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 39.9% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 4,742 shares of the biopharmaceutical company’s stock after selling 3,153 shares during the quarter. Vontobel Holding Ltd.’s holdings in Halozyme […] - 2025-07-09 05:00:49

Envestnet Portfolio Solutions Inc. Has $721,000 Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Envestnet Portfolio Solutions Inc. lowered its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 35.2% in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 11,292 shares of the biopharmaceutical company’s stock after selling 6,143 shares during the period. Envestnet Portfolio Solutions Inc.’s […] - 2025-06-26 04:38:48

Janney Montgomery Scott LLC Grows Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Janney Montgomery Scott LLC boosted its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 2.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 294,123 shares of the biopharmaceutical company’s stock after purchasing an additional 6,392 shares during […] - 2025-06-19 05:50:56

SeaCrest Wealth Management LLC Invests $213,000 in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

SeaCrest Wealth Management LLC purchased a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 3,333 shares of the biopharmaceutical company’s stock, valued at approximately $213,000. Several other institutional […] - 2025-06-09 05:54:51

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Wellington Management Group LLP

Wellington Management Group LLP lessened its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 12.0% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 57,370 shares of the biopharmaceutical company’s stock after selling 7,787 shares during the quarter. Wellington Management Group LLP’s holdings in Halozyme Therapeutics were worth $2,743,000 at the […] - 2025-06-06 05:34:51

Tidal Investments LLC Has $381,000 Stock Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Tidal Investments LLC trimmed its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 61.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,978 shares of the biopharmaceutical company’s stock after selling 12,598 shares during the period. Tidal Investments LLC’s holdings […] - 2025-05-30 05:47:04

Baird Financial Group Inc. Buys 221 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Baird Financial Group Inc. raised its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 2.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,119 shares of the biopharmaceutical company’s stock after acquiring an additional 221 shares during the period. […] - 2025-05-16 05:31:14

Halozyme Therapeutics Reaches Analyst Target Price

In recent trading, shares of Halozyme Therapeutics Inc (Symbol: HALO) have crossed above the average analyst 12-month target price of $68.12, changing hands for $70.14/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgra - 2025-05-08 09:19:58

Hsbc Holdings PLC Acquires 3,289 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Hsbc Holdings PLC increased its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 52.0% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 9,615 shares of the biopharmaceutical company’s stock after purchasing an additional 3,289 shares during the quarter. Hsbc […] - 2025-05-08 05:10:47

Halozyme Therapeutics (NASDAQ:HALO) Sets New 12-Month High After Strong Earnings

Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report)’s share price reached a new 52-week high during mid-day trading on Wednesday following a stronger than expected earnings report. The company traded as high as $69.07 and last traded at $68.06, with a volume of 1856311 shares trading hands. The stock had previously closed at $59.38. The […] - 2025-05-08 03:08:54

4,426 Shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO) Acquired by Marshall Wace LLP

Marshall Wace LLP bought a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) during the 4th quarter, Holdings Channel.com reports. The fund bought 4,426 shares of the biopharmaceutical company’s stock, valued at approximately $212,000. Other institutional investors and hedge funds have also made changes to their positions in the company. Heck […] - 2025-05-06 04:30:49

Halozyme Files Patent Infringement Lawsuit Against Merck

(RTTNews) - Halozyme Therapeutics (HALO) filed a patent infringement lawsuit against Merck Sharp & Dohme Corp. in U.S. District Court in New Jersey. Halozyme believes the subcutaneous formulation of Merck's cancer medicine, Keytruda, infringes multiple patents that Halozyme filed - 2025-04-24 10:08:04

Legal & General Group Plc Decreases Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Legal & General Group Plc lowered its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 1.4% in the fourth quarter, HoldingsChannel.com reports. The fund owned 225,427 shares of the biopharmaceutical company’s stock after selling 3,197 shares during the quarter. Legal & General Group Plc’s holdings in Halozyme Therapeutics were worth $10,778,000 […] - 2025-04-17 06:08:53

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by CIBC Private Wealth Group LLC

CIBC Private Wealth Group LLC lessened its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 99.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,053 shares of the biopharmaceutical company’s stock after selling 963,451 shares during […] - 2025-04-08 05:22:55

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by California Public Employees Retirement System

California Public Employees Retirement System cut its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 6.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 213,687 shares of the biopharmaceutical company’s stock after selling 15,172 shares during the quarter. […] - 2025-04-07 05:56:55

Schroder Investment Management Group Sells 9,933,836 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Schroder Investment Management Group cut its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 99.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 87,503 shares of the biopharmaceutical company’s stock after selling 9,933,836 shares during the quarter. Schroder Investment Management […] - 2025-04-06 05:30:52

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Receives $62.78 Consensus Price Target from Analysts

Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) has received an average recommendation of “Moderate Buy” from the ten ratings firms that are covering the firm, Marketbeat.com reports. Four analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year price objective among analysts […] - 2025-04-01 02:56:51

Back to Listing

Disclaimer